|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Mount Sinai School of Medicine |
| Information provided by: | Office of Rare Diseases (ORD) |
| ClinicalTrials.gov Identifier: | NCT00004479 |
Purpose
OBJECTIVES:
Determine the efficacy of midodrine, a selective alpha 1 adrenergic agonist, in preventing neurally mediated syncope.
| Condition | Intervention |
|
Syncope |
Drug: midodrine |
| MedlinePlus related topics: | Fainting |
| Drug Information available for: | Midodrine Midodrine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind |
Eligibility
| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- Diagnosis of neurally mediated syncope (vasovagal fainting) Sudden fall in blood pressure AND Slowing of the heart AND Temporary loss of consciousness AND Hemodynamic response to head up tilt --Prior/Concurrent Therapy-- No other concurrent adrenergic agonist or antiagonist --Patient Characteristics-- Fertile patients must use effective birth control
Contacts and Locations| United States, New York | |||||
| Mount Sinai School of Medicine | |||||
| New York, New York, United States, 10029 | |||||
| Mount Sinai School of Medicine |
| Study Chair: | Horacio Kaufmann | Mount Sinai School of Medicine |
More Information
| Study ID Numbers: | 199/14181, MTS-GCO-97-160NE, ROBERTS-MTS-GCO-97-160NE |
| First Received: | October 18, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00004479 |
| Health Authority: | Unspecified |
|
|
|
|
|